NCT04810208终止1 期
A Phase Ia/Ib, First-in-human, Open Label, Multicentre, Dose-escalation and Dose-expansion Study of a Novel NanoZolid®-Docetaxel Depot Formulation (NZ-DTX Depot) Given as an Intra-tumoural Injection in Patients With Advanced Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- Lidds AB
- 入组人数
- 6
- 试验地点
- 4
- 主要终点
- Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.
研究概览
简要总结
This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours. The study includes a dose escalation part and a dose expansion part.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent granted before undertaking any study-specific procedures;
- •Male or female patient ≥18 years of age on the day of consenting to the study;
- •Histologically or cytologically confirmed diagnosis of solid cancer;
- •At least 1 advanced solid, palpable, cutaneous or subcutaneous tumour lesion with following characteristics:
- •a cutaneous lesion with of thickness ≥4 mm and diameter ≥25 mm at the longest axis, or
- •a subcutaneous lesion of diameter ≥20 mm at the longest and the shortest axis;
- •Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0-2;
- •Patient from one the following categories:
- •Patient for whom no standard therapy exists, or standard therapy is contraindicated, or
- •Patient who is scheduled for other anti-cancer treatment (e.g. radiotherapy, immunological treatment, surgery) which will start after completion of at least one treatment cycle of NZ-DTX, i.e after the end-of-study (EOS) visit.
排除标准
- •Known hypersensitivity to any of the excipients in the NZ-DTX Depot formulation (docetaxel, calcium sulphate, sodium carboxymethylcellulose);
- •Life expectancy <3 months;
- •Bleeding deficiencies or ongoing anticoagulant therapy that would put the patient at increased risk of clinically significant bleeding, in the judgement of the Investigator. If the patient has an international normalised ratio (INR) below 1.2 the Investigator may judge if interruption of anticoagulant therapy is warranted;
- •Any of the following abnormal laboratory values at screening;
- •Bone marrow function:
- •Absolute neutrophil count (ANC) <1.5 x 109/l;
- •Platelet count <100 x 109/l;
- •Haemoglobin <9.0 mg/dl.
- •Coagulation:
- •International Normalized Ratio (INR) >1.
- •Hepatic, renal, and biochemistry parameters:
- •Aspartate transaminase (AST) or alanine transaminase (ALT) >2.5 x upper limit of normal (ULN) (>5 x ULN if liver metastases present)*;
- •Alkaline phosphatase (ALP) >2.5 x ULN;
- •Total bilirubin >1.5 x ULN;
- •Estimated glomerular filtration rate (eGFR) <40 ml/min/1.73 m² using the Modified Cockcroft & Gault formula.
- •For patients with liver impairment who have serum transaminase levels (ALT and/or AST) greater than 1.5 times x ULN - the doses will be restricted to max. 75mg/m
- •In the event this is not possible the patient will not be included.
- •Severe fluid retention, e.g. pulmonary oedema, pleural effusion, pericardial effusion or ascites;
- •Clinically significant heart disease (i.e. heart failure or myocardial infarction within 6 months of screening, instable angina pectoris);
- •History of thromboembolic or cerebrovascular events within 6 months of screening;
- •Major surgery within 2 weeks of screening, or patient not recovered from major surgery;
- •Known untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of screening;
- •Not recovered from Grade 2 or higher adverse events (AEs) due to previous treatments, excepting alopecia;
- •Concurrent participation in another investigational study;
- •Last investigational drug administration in a prior investigational study within 14 days of study treatment initiation or <5 times the half-life of the investigational drug, whichever is longer;
- •Last administration of other anti-neoplastic drug within 14 days of study treatment initiation;
- •Radiotherapy of lesion to be injected within 4 weeks of first treatment with NZ-DTX Depot, or irradiated lesion to be injected without signs of disease progression since irradiation;
- •For men and women of childbearing potential: Unwillingness to follow contraception requirements;
- •Female patients with planned or current pregnancy and/or currently breastfeeding;
- •Any other severe, acute or chronical medical or psychiatric condition or laboratory abnormality that, in the judgement of the Investigator, would make the patient inappropriate for study participation.
研究组 & 干预措施
NZ-DTX Depot
Experimental
干预措施: Docetaxel (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) of NZ-DTX Depot given as an intra-tumoural injection in solid, palpable, cutaneous or subcutaneous tumour lesions.
时间窗: 5 weeks
The MTD will be determined by incidence of DLTs
The recommended Phase 2 dose (RP2D) of NZ-DTX Depot given as an intra-tumoural injection in a solid, palpable cutaneous or subcutaneous tumour lesion.
时间窗: 5 weeks
The RP2D will be determined by frequency and severity of adverse events
次要结局
- Frequency and severity of treatment-emergent adverse events [safety and tolerability] following an intratumoural injection of NZ-DTX Depot(5 weeks)
- Plasma concentration of docetaxel, following an intratumoural injection of NZ-DTX Depot(5 weeks)
- Anti-tumour effect following an intratumoural injection of NZ-DTX Depot(5 weeks)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT01957995University of Southern California13
终止
1 期
Study of 23ME-01473 in Patients With Advanced Solid MalignanciesSolid TumorNCT0629038823andMe, Inc.5
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular CarcinomaHepatocellular CarcinomaNCT05595473Rznomics, Inc.42
已完成
1 期
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate AccumulationsAdvanced Solid Tumor MalignancyNCT04260529Cytovation AS60
招募中
1 期
A Study of MGC026 in Participants With Advanced Solid TumorsBreast CancerCervical CancerGastric CancerBladder CancerMelanomaSarcomaColorectal CancerClear Cell Renal Cell CarcinomaHepatocellular CarcinomaOvarian CancerNCT06242470MacroGenics250